Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents

Anti-Cancer Drugs

Volumn 9, Issue 5, 1998, Pages 437-448

  Dolan, M Eileen ^a   Frydman, Benjamin ^c   Thompson, Craig B ^a   Diamond, Alan M ^a   Garbiras, Bonnie J ^a   Safa, Ahmad R ^a,e   Beck, William T ^b   Marton, Laurence J ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c S'LIL Pharmaceuticals LLC   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anticancer drug; Cytotoxicity; Glutathione; Naphthoquinones; Resistance

Indexed keywords

1,2 NAPHTHOQUINONE; DNA TOPOISOMERASE; GLUTATHIONE; GLYCOPROTEIN P; LAPACHOL; MERBARONE; TENIPOSIDE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BCL-X PROTEIN; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NAPHTHOQUINONES; OXIDATION-REDUCTION; P-GLYCOPROTEIN; PEROXIDASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; TUMOR CELLS, CULTURED;

EID: 0031870525     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199806000-00011     Document Type: Article

References (45)

1. Gantchev TG, Hunting DJ. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16). Biochem Biophys Res Commun 1997; 237: 24-7.
2. O'Brien PJ. Molecular mechanism of quinone cytotoxicity. Chem-Biol Interact 1991; 80: 1-41.
3. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191-218.
4. Driscoll JS, Hazard GF Jr, Wood HB Jr, et al. Structure-antitumor activity relationships among quinone derivatives. Cancer Chemother Rep 1974; 4: 1-362.
5. Lopes JN, Cruz FS, Docampo R, et al. In vitro and in vivo evaluation of the toxicity to 1,4-naphthoquinones and 1,2-naphthoquinone derivatives against Trypanosoma cruzi. Ann Trop Med Parasit 1978; 72: 523-31.
6. Molina-Portela MP, Fernandez-Villamil SH, Perissinotti LJ, Stoppani AO. Redox cycling of o-naphthoquinones in trypanosomatids. Superoxide and hydrogen peroxide production. Biochem Pharmacol 1996; 52: 1875-82.
7. Li CJ, Zhang LJ, Dezubw BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci 1993; 90: 1839-42.
8. Schuerch AR, Wehrli W. β-Lapachone, an inhibitor of oncornavirus reverse transciptase and eukaryotic DNA polymerase-α. Eur J Biochem 1978; 84: 197-205.
9. Schaffner-Sabba K, Schmidt-Ruppin KH, Wehrli W, et al. β-Lapachone: synthesis of derivatives and activities in tumor models. J Med Chem 1984; 27: 990-4.
10. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res 1989; 49: 605-12.
11. Li CJ, Wang C, Pardee AB. Induction of apoptosis by β-lapachone in human prostate cancer cells. Cancer Res 1995; 55: 3712-5.
12. Planchon SM, Wuerzberger S, Frydman B, et al. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 1995; 55: 3706-11.
13. Li CJ, Averboukh L, Pardee AB. β-Lapachone, a novel DNA topoisomerase 1 inhibitor with a mode of action different from camptothecin. J Biol Chem 1993; 268: 22463-8.
14. Frydman B, Marton LJ, Sun JS, et al. Induction of DNA topoisomerase II-mediated DNA cleavage by β-lapachone and related naphthoquinones. Cancer Res 1997; 57:620-7.
15. Batist G, Tulpule A, Sinha BK, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-9.
16. Krishnamachary N, Ma L, Zheng L, et al. Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol Res 1994; 6: 119-27.
17. Toshiyuki M, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-7.
18. L can confer a multidrug resistance phenotype. Blood 1995; 86: 1903-10.
19. Danks MK, Yalowich JC, Beck WT. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 1987; 47: 1297-301.
20. Kusumoto H, Rodgers QE, Boege F, et al. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res 1996; 56: 2575-83.
21. Sun JS, Geiser AH, Frydman B. A preparative synthesis of Lapachol and related naphthoquinones. Tet Lett 1998; submitted.
22. Hooker SC. The constitution of lapachic acid (lapachol) and its derivatives. J Chem Soc 1892; 61: 611-50.
23. Cooke RG. Dunnione and related naphthoquinones. Aust J Sci Res 1950; 3: 481-94.
24. Fieser LF. The alkylation of hydroxynaphthoquinone I. Ortho-esters. J Am Chem Soc 1926; 48: 2922-37.
25. Safa AR. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 1988; 85: 7187-91.
26. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980-90.
27. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-10.
28. Tietze F. Enzymatic method for qualitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969; 27: 502-22.
29. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-9.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein, utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
31. Samuels BL, Murray JL, Cohen MB, et al. Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res 1991; 51: 521-7.
32. Liu LF, D'Arpa P. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance (review). Important Adv Oncol 1992; 79-89.
33. Kramer RA, Zakher J, Kim G. Role of glutathione redox cycle in acquired and de novo multidrug resistance. Science 1988; 241: 694-7.
34. Lutzky J, Astor MB, Taub RN, et al. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/ ADR cells. Cancer Res 1989; 49: 4120-5.
35. Foley GE, Lazarus H, Farber S, et al. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965; 18: 522-9.
36. Beck WT. Mechanisms of multi-drug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II. Cancer Treat Rev 1990; 17 (suppl A): 11-20.
37. Safa AR. Multidrug resistance. In: Schilsky RL, Milano GA, Ratain MJ, eds. Principles of an tine oplastic drug development and pharmacology. New York: Marcel Dekker 1996: 457-486.
38. Beck WT. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst 1989; 81: 1683-5.
39. Monks TJ, Lau SS. Toxicology of quinone-thioesters. Crit Rev Toxicol 1992; 22: 243-70.
40. Neder K, Marton LJ, Liu LF, Frydman B. Reaction of β-lapachone and related naphthoquinones with 2-mercaptoethanol: a biomimetic model of topoisomerase II poisoning by quinones. Cell Mol Biol 1998; in press.
41. Docampo R, Cruz FS, Boveris A, et al. Lipid peroxidation and the generation of free radicals, superoxide anion, and hydrogen peroxide in β-lapachone-treated Trypanosoma cruzi epimastigotes. Arch Biochem Biophys 1978; 186: 292-7.
42. Docampo R, Gruz FS, Boveris A, et al. β-Lapachone enhancement of lipid peroxidation and superoxide anion and hydrogen peroxide formation by sarcoma 180 ascites tumor cells. Biochem Pharmacol 1979; 28: 723-8.
43. Sunde RA. Molecular biology of selenoproteins. Annu Rev Nutr 1990; 10: 451-74.
44. Doroshow JH. Glutathione peroxidase and oxidative stress. Toxicol Lett 1995; 82-83: 395-8.
45. Liebman J, Fisher J, Lipschultz C, et al. Enhanced glutathione peroxidase expression protects cells from hydroperoxides hut not from radiation or doxorubicin. Cancer Res 1995; 55: 4465-70.